| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6183211 | Gynecologic Oncology | 2015 | 6 Pages |
â¢Pazopanib maintenance therapy extended PFS in patients with AEOC.â¢HR estimates for PFS by investigator were consistent with those of central review.â¢There was no evidence of investigator bias in estimates of disease progression.
BackgroundAnalysis of progression-free survival (PFS) as the primary endpoint in advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer (AEOC) trials may be confounded by the difficulty of radiologic evaluation of disease progression and the potential for discrepancy between investigator and blinded independent central assessments. PFS as assessed by local investigator (INV) was the primary endpoint of AGO-OVAR16, a randomized, double-blind trial of pazopanib maintenance therapy in AEOC. To confirm the robustness of the primary analysis, PFS was also evaluated by blinded independent central review (BICR).MethodsPatients with histologically confirmed AEOC (NÂ =Â 940) were randomized 1:1 to receive pazopanib 800Â mg/day or placebo for up to 24Â months. Tumor response in the intent-to-treat population was evaluated by CT/MRI every 6Â months and analyzed per RECIST 1.0.ResultsPazopanib prolonged PFS versus placebo by INV (median 17.9 vs 12.3Â months; hazard ratio [HR]Â =Â 0.766, 95% confidence interval [CI]: 0.643-0.911; PÂ =Â 0.0021). Results for PFS by BICR were similar (median 15.4 vs 11.8Â months; HRÂ =Â 0.802, 95% CI: 0.678-0.949; PÂ =Â 0.0084). Progression events were recorded later by INV in 23% of pazopanib-treated patients and 17% of placebo-treated patients. The overall concordance between INV and BICR assessments was 84% and 86% in the pazopanib and placebo arms, respectively.ConclusionsBy INV and BICR assessments, maintenance therapy with pazopanib in AEOC provided a significantly longer PFS than placebo. The good overall concordance between INV and BICR assessments, as well as HR and P value consistency, supports the reliability of investigator-assessed PFS as the primary endpoint in AGO-OVAR16.
